Clinical Trials Logo

Filter by:
NCT ID: NCT03769363 Withdrawn - Clinical trials for Social Anxiety Disorder

Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for social anxiety disorder (SAD). The investigators hypothesize that participants receiving app-CBT will have greater reduction in LSAS scores than those in the waitlist condition at treatment endpoint (week 12).

NCT ID: NCT03769350 Withdrawn - Clinical trials for Major Depressive Disorder

Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for major depressive disorder (MDD). The investigators hypothesize that participants receiving app-CBT will have greater improvement in QIDS-C scores than those in the waitlist condition at treatment endpoint (week 8).

NCT ID: NCT03768869 Withdrawn - Fever Clinical Trials

Fever and Neutropenia in Pediatric Oncology Patients

Start date: February 2006
Phase: Phase 3
Study type: Interventional

It is possible to distinguish between pediatric oncology patients who are at high or low risk for serious infection during periods of fever and treatment related neutropenia based on clinical parameters. Patients with low risk can be safely treated as outpatients primarily using oral antibiotics. It is possible to improve methods of risk stratification through the addition of genomic and proteomic factors.

NCT ID: NCT03768310 Withdrawn - Clinical trials for Acute Lymphoblastic Leukemia

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Start date: June 2022
Phase: Phase 1
Study type: Interventional

This study is for patients that are having a bone marrow or stem cell transplant for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called Non-Hodgkin's Lymphoma (NHL). Although a transplant can cure leukemia or lymphoma, some people will relapse (return of the disease). In those who relapse, current treatment cures only a very small percentage. This study is being conducted to evaluate the safety of a new type of therapy that may help to decrease the risk of relapse or treat relapse after it has occurred. The body has different ways of fighting infection and disease. This study combines two of those ways, antibodies and T cells. Antibodies are proteins that protect the body from bacterial and other diseases. T cells are infection-fighting blood cells that can kill other cells, including tumor cells. Antibodies and T cells have been used to treat patients with cancers; they have shown promise, but have not been strong enough to cure most patients. The antibody used in this study is called anti-CD19. This antibody is attracted to cancer cells because of a substance on the outside of these cells called CD19. For this study, the anti-CD19 antibody has been changed so that instead of floating free in the blood it is now joined to T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor (also known as a CAR T cell). Although anti-CD19 antibodies or chimeric receptors can kill cancer cells, unfortunately they sometimes do not last long enough to destroy all of the cancer cells. These CD19 chimeric receptor multivirus specific T cells are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the biggest dose of chimeric T cells that is safe to administer, to determine what the side effects are, to see how long the T cells last and to evaluate whether this therapy might help prevent infections and relapse in people with CD19+ leukemia or lymphoma having a bone marrow transplant.

NCT ID: NCT03767491 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

Waitlist-Control Trial of Smartphone CBT for Obsessive-Compulsive Disorder (OCD)

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for obsessive compulsive disorder (OCD). The investigators hypothesize that participants receiving app-CBT will have greater improvement in Y-BOCS scores than those in the waitlist condition at treatment endpoint (week 12).

NCT ID: NCT03764137 Withdrawn - Clinical trials for Metastatic Colon Cancer

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

Panitumumab
Start date: March 14, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

NCT ID: NCT03762889 Withdrawn - Corneal Injuries Clinical Trials

Peri-operative Application of Eyeprotx General Anesthesia Goggles As Prevention Against Corneal Injury Post Intubation.

Start date: June 2019
Phase: N/A
Study type: Interventional

This is a randomized controlled trial that seeks to examine the effectiveness of Eyeprotx™ protective goggles in comparison to traditional methods against ocular injury that can occur perioperatively under general anesthesia.

NCT ID: NCT03762798 Withdrawn - Clinical trials for Substance Use Disorders

Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone

Start date: November 19, 2018
Phase: N/A
Study type: Interventional

This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.

NCT ID: NCT03762603 Withdrawn - Clinical trials for Primary Knee Replacement Surgery

Does Supplementing of Quadriceps Strength With Exoskeleton After Total Knee Arthroplasty in High Risk Population Reduce Transfer to Extended Care Facility (ECF)

Start date: September 2021
Phase: N/A
Study type: Interventional

This study involves an exoskeleton which is believed to increase quadriceps muscle strength in the rehabilitation phase after TKA and reduce the discharge the such patients in Extended care facility (ECF) . The purpose of this study is to access efficacy of the robotic exoskeleton device wrapped around the operated knee on patients

NCT ID: NCT03761953 Withdrawn - Clinical trials for Staphylococcus Aureus Bacteremia

Oritavancin for Staphylococcus Aureus Infections in Opioid Users

Start date: July 1, 2019
Phase: Phase 4
Study type: Interventional

This will be a pilot single-arm study consisting of 15 participants evaluating the use of oritavancin in the final consolidation phase (last two weeks of treatment) of systemic infections with Staphylococcus aureus (S. aureus) in opioid users. The purpose of this pilot proposal is to collect information for a subsequent large, randomized intervention. Primary endpoints will be 1) Safety and tolerability, and 2) Duration of hospitalization and rate of recurrence.